Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here is a post - 212427 by PlentyP
Industry: Biotech and Pharma
Revenue TTM: 100M to 2000M
Revenue Growth TMM over TTM: < 200 %, to cut off cos having a insane revenue jump TTM over TTM
Surprise: Average price to sales ratio still about 9 and average revenue growth 23 %.
Apply that to future IPIX with 1 B$ revenue from one drug with growth potential in excess of 23 % year over year, which IPIX should be able to achieve easily with the rest of its pipeline. You get potential (and conservative) market cap 9 billion. Let's assume 200 million share (now about 140 million).
That gives for potential (and conservative) share price 9000/200 = 45 bucks.
Version 2: Assume 15 % royalty income. That is 150 million. But this income goes directly to earnings (no cost of goods etc). Can't use price to sales ratio because it does not apply here. Must use P/E for 75 cent per share earnings. Screen gave average P/E 50.
That gives future IPIX (conservative) share price of 37.5 USD.
I agree. And hope you are right.
If P can bring in over a billion that warrants an above 30 dollar share price when in fact that does happen. That is P alone. That is why investors like this company. The risk vs reward is in investors favor
There are only a few oral drugs. Otezla is king. We shall see how P stands up to that. Otezla does bring side effects. So let’s see if P is safer and more effective. Multi billion a year opportunity if it does
It’s BLINDED! Stop spreading lies
One more time: they have millions invested. They have tens of millions of shares. They work hard. As you can see by the trial progress over 5 years it is PERFECT. 8 trials. Well 7 and soon to be 8
Correct. Aruda was associated with the CRO? Or something. BK knows better
He’s here for SPORT - that is all. Lol
5 Total PRs this year.
2 had trial updates
3 were just Corp updates
That is not The norm for Leo. That makes me think we are about to move to a new ballpark. Just saying.
Leo knows we are on the otcbb. He knows we use aspire ..... so to not PR weekly which he easily could is telling.
It’s been a blessing for me and some close relatives to get my cost basis down and add double my holdings over the past months..... I expect this to turn much faster than the decline.
Im ready to get excited again. Kevetrin I have missed you
I’m not sure if you missed this PR but it was a knowledge bomb:
Cellceutix Provides Update on Developing p53 Drug Candidate Kevetrin as an Oral Anti-Cancer Agent
Kevetrin
BEVERLY, Mass., March 03, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, is pleased to update shareholders on continuing efforts to develop the oral dosing of Kevetrin.
Based on positive results from Cellceutix’s Phase 1 trial of Kevetrin in solid tumors conducted at Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center, the Company is moving forward with a Phase 2 trial of intravenously-administered Kevetrin in patients with late-stage, platinum-resistant ovarian cancer. Cellceutix has decided to pursue an oral formulation for Kevetrin to improve patient convenience and potentially increase therapeutic efficacy given the drug’s short half-life and other pharmacokinetics, as discussed below.
As background, pre-clinical work determined the bioavailability of Kevetrin was 79 percent when given orally in Sprague-Dawley rats. To further establish the efficacy of oral Kevetrin, in vivo mouse studies were carried out in an ascites ovarian tumor model using OVCAR-3 and OV-90 tumor models, both of which possess different mutant p53 genes. Importantly, these pre-clinical results showed that the overall efficacy of Kevetrin was similar across both oral and intraperitoneal routes of drug administration.
Cellceutix has initiated a series of GLP (Good Laboratory Practice) studies to assess the safety of Kevetrin given orally. Considering that Kevetrin is a non-cytotoxic drug, our intent, with FDA permission, is to next proceed with a Phase 1 clinical trial in healthy volunteers using the oral route. These studies are being conducted by approved vendors and include: photosafety testing, pharmacokinetics, in vivo metabolism, metabolic stability, protein binding, and genetic and physiological toxicology reports.
Preliminary data analyses in a pharmacokinetic study in rats revealed a half-life of approximately 1 hour and a clearance of 78ml/min/kg for both oral and intravenous (IV) dosing. Results of an initial photosafety study demonstrated a molar extinction coefficient value of less than 5 L/mol*cm over a range of wavelengths above 290 nm, well below the 1000 L/mol*cm limit stated in ICH guidelines—indicating Kevetrin has no phototoxicity. A preliminary toxicity study showed that at doses up to 500 mg/kg given orally daily for 7 days, Kevetrin was well-tolerated by the rats as indicated by an 11 percent increase in body weight and no abnormal clinical observations. Further, this dose was greater than the doses used in the preclinical efficacy study. Remaining safety studies will be completed in the second half of this year.
In related news: Last week, Cellceutix research partners in Italy shared results with the Company from their ongoing preclinical work evaluating Kevetrin in Acute Myeloid Leukemia (AML), Pancreatic Cancer and human Gliobastoma Multiforme (hGBM). The data will be presented (by them) at scientific conferences, and is consistent with, and further informs, our knowledge of Kevetrin. Also, efficacy data from the 2nd cohort in the Brilacidin-Ulcerative Colitis proof-of-concept study is in the last stage of being compiled by the CRO and, following a final review, will be released.
I’ll have 4K on Monday
LBK - I believe in the end there is a very good possibility we see 10 billion valuation and beyond. I’m not saying P is worth 10 Billion today, but I do feel this company will be worth multiples of that if the pipeline continues to have success.
B-OM alone, could take the MC to billions. IMO.
“To further these efforts, the Company is in negotiations with a leading drug formulator to develop topical formulation(s) of Brilacidin for these three dermatology indications, starting in 1H2018. The goal of the negotiations is to reach terms on a strategic partnership for addressing these markets. The formulator brings an impressive track record of developing products that have earned billions of dollars for global pharmaceutical companies.”
What does “strategic partnership” mean in this case? Anyone?
Thx Farrell - sometimes we all forget what is really going on with IPIX!
I do not have PM. We will be perfectly fine imo. There is just too many options for IPIX. Just make one deal with several million upfront and let’s go. We just need 3rd party validation. Every bio would cream over this pipeline and the future possibility.
Good luck.
I’ve been in 3 MAs. Never knew once. And i was a project manager.
Look at all the big gainers from good data - stocks were down until news released. Why are you here?
No no. I saw .54? Weird. But hold tight 100K might pound this soon
Think about how awkward and not Leo like the PR train has been! If Leo had nothing he’d be spouting that Trump is going to save us ;). Jk Leo but....kinda not
Greeeeeen!!! Thx for the shares
The Prurisol Phase 2b clinical trial in Moderate-to-Severe Psoriasis remains blinded at present. Once the full dataset has been unblinded, received and reviewed, the Company will release the results. A novel psoriasis drug, particularly one that is oral, safe and effective, would be well-received by clinical practitioners and patients alike, and would likely command significant market value.
Trial is still blinded. Fact
Here is a post - 212427 by PlentyP
Industry: Biotech and Pharma
Revenue TTM: 100M to 2000M
Revenue Growth TMM over TTM: < 200 %, to cut off cos having a insane revenue jump TTM over TTM
Surprise: Average price to sales ratio still about 9 and average revenue growth 23 %.
Apply that to future IPIX with 1 B$ revenue from one drug with growth potential in excess of 23 % year over year, which IPIX should be able to achieve easily with the rest of its pipeline. You get potential (and conservative) market cap 9 billion. Let's assume 200 million share (now about 140 million).
That gives for potential (and conservative) share price 9000/200 = 45 bucks.
Version 2: Assume 15 % royalty income. That is 150 million. But this income goes directly to earnings (no cost of goods etc). Can't use price to sales ratio because it does not apply here. Must use P/E for 75 cent per share earnings. Screen gave average P/E 50.
That gives future IPIX (conservative) share price of 37.5 USD.
70% here don’t know how to read that. Thank you though! Our pipeline is stacked.
Negotiating between several BPs take precedence Bun. Those who stay long will roll in cash. IPIX is working hard every day to sift through the offers. What will maximize value in the long term for shareholders is the only thing on mgmts minds.
This depressed share price again means nothing. The drugs and indications mean everything
False. There are no delays. This is a 10 yr investment. During a life cycle of a pre rev biotech - the share price and real value of a company will be disconnected. There is extreme disconnect right now.
Soon this will re-evaluate like history of other bios.
This should be in the 5 dollar range right now. BTD for OM, and P data should set this above that.
They are not dumbfounded imo. They know the game and are on a straight path to partnership. They have done everything they have set out to do by anchoring B. Get ready max. This will be 20x soon. ATLEAST.
“What must be stressed is that Brilacidin is a mature, later-stage drug candidate with platform potential. It took the recent completion of two Phase 2 trials, in IBD and OM, to further validate the exceptional results achieved from our Phase 2b study in ABSSSI. These recent data, taken in aggregate, are what various actively engaged pharmaceutical companies have desired from us for some time—and they are what triggered a newfound flurry of inbound partnership discussions at the San Francisco conferences,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “Datasets now in hand, reflecting three successfully completed Phase 2 studies across which multiple endpoints were met, have brought the Company to an important inflection point regarding Brilacidin. In coming weeks, we look forward to advancing these discussions with attractive partnership / licensing scenarios, towards determining the best path forward for the Company and its loyal shareholders.”
First and foremost, I will not waste MGMTs time at this juncture. If I was concerned with the company I would absolutely fly East to meet with MGMT because yes I do have enough skin in this game for answers. IPIX makes it clear what they are working on and how things are going. And when I read the PRs and the Qs and Ks I am perfectly content with what they are doing. I am actually over the moon.
Share price WILL reflect true value soon. I believe we are just about there. Just because this is low volume and Aspire may be utilized does not mean this company is worth 52 cents a share. This is when real investors make the big money.
Just watch he chase. It will be epic. I've never been on a board with more negative posters in my life. That means something to me... I'm in the right spot because someone wants this lower. IMO.
I’m feeling it soon. Very very soon.
BTD - Data Lock - Partner. One or the other. .52 is the absolute best value in the market imo. If it goes lower it will then be the best lol.
I’ve posted a million times- in 2012 we were at 1.00 when we started phase 1 K. That was the only trial and we just had 30k cash w 93 million OS
We’ve completed 8 trials since and added Brilacidin. Which in the end could be a Humira type drug.
B-OM should take this stock to 30 plus by the second year on market. IMO. PP did the math and it’s legit.
Play golf. Set your news alerts. This crap means nothing here.
See you at an all time High!
How? You are here for nickel and dime flips. So maybe in that regard I’m brave. What has changed here? An additional 2-3-10 million shares from Aspire? That for sure could drop the SP to where it is now, but that amount is very minimal to the overall science. IMO.
B-OM is in a leadership position. I read some good stuff that PP provided and this alone can take this share price to the promise land for me.
Again I don’t chart and I don’t trade. I like what I see here and until I do not I am long and will add. I bought some in the 3’s and am not sour about it. I will buy more in the 3’s when we return.
Share price means nothing. I know that. ATLEAST it does not at IPIX’s phase of development. We can partner with BP or small bios today. But IPIX will maximize the value of our shares. I believe.
Welcome to the hub. It’s a scary place. I have spoken to and that is all. There is 100% confidence in Beverly. Nothing less.
They are shocked at share price but understand what goes on.
All they can do is provide good science and do it while keeping us updated.
I have only seen SUCCESSFUL trials. Nothing has failed
Again Yah. What is there to be concerned about? Screw the stock share price performance. I’d like to know what I should be concerned about with IPIX?
I’ve been around the world, I’ve seen a lot and know Bio is not for everyone. I’ve seen bios go from 10’s of dollars, to cents to hundreds of dollars. These stocks get manipulated more than any other industry at a norm. IMO.
I’m really not concerned. I just want to know who some of these peeps are. And I’ll put up some major cash to find out
That’s okay. I bought some today and will continue to buy more and support IPIX. I’m long and will continue to be as I’ve seen or read nothing to be alarmed about.
Keep them coming. All shares I buy are locked for 10 years
I would not be surprised. The good thing: Sullivan and Leo are still watching.
IPIX has multiple interested parties.
IPIX has the real deal when it comes to drugs and pipeline.
If it is true, it would make so much sense why it’s been crazy here so close to P data reveal. The P data could crush many as it gives just another reason to partner w IPIX which in-tail gives them strength in negotiations. One domino is all that is needed.
In my long time as a shareholder here I’ve NEVER seen anything close to this many FUD posts. Why do people take the time—-all day to say negative and false things about a public traded company? Who has time to do this? For free ATLEAST?
Pre clinical models for psoriasis are very telling. Those models often hold true through human trials and safety is the real concern. However, safety is not a concern here due to the 505 2b
I’d bet we see some phenomenal results for the Prurisol phase 2b.
I wonder if that is why so many negative FUD’sters are here? Maybe someone is nervous this trial is going to exceed Otezlas efficacy and safety!?
I wonder.
Who’s out of gas? I’ll just remind people, this board is full of non sense and fantasy - trying to promote fear and ride the uncertainty wave.
IPIX is in no way out of gas. They are in a very important negotiation phase for One and possibly several of their drug indications.
Per Leo, and public statements they have reached a point where mutually benefitting term sheets are in progress. These agreements could be delivered today or in months. No one knows, but mgmt has stated clearly what they are working on as we wait.
There is zero fear from mgmt and there is zero uncertainty in their pipeline.
I agree. For me this is life changing. I’ll score probably 13k more shares. I had a goal 5 years ago and have exceeded it. There is nothing wrong with IPIX but the share price. Buy the fear on a scientifically sound company and reap the rewards!
Only buy what you can lose of course.
IPIX!!!!!
If you reread yesterday's PR it does bring a different light to B-OM.
One, if you are a BP and possible partner, the understanding that IPIX is working on moving to sachets is a big deal in the real world and will cost millions less going that route in Manufacturing, Shipping and Logistics. Imagine a company that has to bottle and ship listerine size bottles or packages - and for a 7 week course? That is alot of bottles and alot of manufacturing and cost!!!! Really think about that! Giving little splenda style packets that you mix with water is a billion dollar transition alone.....
Next - the fact that they mention they see B-OM as being a NO DOUBT drug to be prescribed for every patient that will have Chemo Radiation for HNC is unreal.... 65,000 (worldwide, ~750,000 cases annually)
Then the plan will be to broaden the label of B-OM to cover all Chemo Radiation patients including HSTC - the numbers become unthinkable --- in the US Alone ---- 650,000 people annually in the U.S alone! World Wide?????? Hundreds of Millions. All will have the ability to be prescribed B-OM for prevention.
If they do get there -- IF ---- this stock would be in untouchable. 2 Billion untapped market for HNC - add the other cancers that require CR - you are talking what??? BILLION(S) upon BILLION(S)
That is why you invest in a company. Great science in unmet area's...
Good post.